The global acute repetitive seizures market size was significantly large in 2020, and is expected to continue to register a rapidly inclining revenue CAGR between 2021 and 2030. Key factors responsible for driving market revenue growth are rising prevalence of neurological diseases and increasing awareness of epilepsy across the globe.
Recurrent, serial, or cluster seizures are some of the synonyms of Acute Repetitive Seizures (ARS). It is a treatment-resistant epileptic phenomena characterized by a close chronological connection of seizures that exceed a patient\'s expected baseline seizure incidence. It increases the likelihood of hospitalization and/or progression to status epilepticus, a life-threatening seizure emergency, thereby emphasizing the importance of prompt and effective therapy. In this orphan indication, benzodiazepines are often used for treatment as they were recommended by government bodies to be an addition to patients\' chronic Antiepileptic Drug (AED) regimen and administered on an as-needed basis.
For the vast majority of patients suffering from cluster seizures, drug therapy is very effective. However, there are numerous treatment problems and unmet medical needs, such as drug-induced seizures, adverse effects, and a shortage of antiepileptic drugs that can prevent the onset of seizures and its comorbidities.
Major Factors Driving Growth Of The Global Acute Repetitive Seizures Market:
Revenue growth of the global acute repetitive seizures market is significantly driven by the rising number of clinical studies, increased emphasis on the introduction of novel medicines, and high demand for nasal sprays for the treatment of epilepsy. Furthermore, the increasing number of supervisory approvals and promising treatments in the pipeline is projected to drive growth of the acute repetitive seizures market during the forecast period.
In addition, in order to reduce healthcare spending, governments are working persistently to reduce hospital stays and on-site treatment expenses through outpatient care models, such as home healthcare and clinics. Developing countries, such as China, are increasingly implementing such healthcare changes, which are expected to drive growth of the acute repetitive seizures market in the near future.
Factors Restraining Growth Of The Global Acute Repetitive Seizures Market:
The global acute repetitive seizures market growth is substantially hampered by several unfavorable factors. One of the major treatment challenges is the lack of knowledge of seizures. This problem is exacerbated by the lack of access to proper health care services, costlier treatment options, unavailability of emergency treatment, and the distance between health care facilities. Moreover, patients prefer the intranasal route over other forms of pharmaceutical administration routes, such as buccal, rectal, and intramuscular. Outpatient treatment with parenteral drugs has proven to be the best treatment option. Besides, healthcare workers in some countries, such as the Netherlands, are not competent to administer parenteral drugs. In addition, individuals with neurological conditions are unaware of new treatments for neurological disorders. These factors may hamper the acute repetitive seizures market growth.
Opportunities For Players Operating In The Global Acute Repetitive Seizures Market:
Orphan drugs are predicted to control the majority of the global market due to their sheer commercialization. Since both USL-261 and VALTOCO have been designated as orphan drugs, their pricing is expected to be high. Moreover, as the nasal route of administration is preferred over others, it will result in the increased use of these two medications. In addition, the number of clinical trials to assess the safety and efficacy of nasal route administration by nasal sprays have risen due to the increasing demand for safe and affordable alternatives. Also, some innovative medications are expected to be marketed in the near future, owing to an increase in the number of FDA approvals, thereby creating new growth opportunities for the acute repetitive seizures market.
Global Acute Repetitive Seizures Market Revenue Led By Product Type Segment:
Based on product type, the NRL-1 segment is expected to reach the highest revenue share over the forecast period. As it was developed as a new treatment for use in children, adolescents, and adults, the segment is anticipated to grow rapidly. The diastat rectal gel segment is expected to lead due to its efficacy and the absence of other FDA-approved medications in this market. It is the only FDA-approved medication, and generic versions were introduced recently. Moreover, USL-261, which is specifically intended for intranasal delivery for outpatient usage, is predicted to grow rapidly in the next few years.
Global Acute Repetitive Seizures Market leading End-use Segment:
Based on end-use, the healthcare & pharmaceuticals segment is expected to dominate all other segments in terms of revenue generation over the forecast period. Major factors contributing to this segment’s growth are the increased availability of pharmaceuticals for critical illnesses, ease of access, and rising chain of retail pharmacies delivering treatments for acute repetitive seizures.
North America Accounts For Largest Revenue Share In Global Acute Repetitive Seizures Market:
Among regional markets, North America emerged as the largest market for acute repetitive seizures in 2020, with the highest revenue share. Revenue growth of the acute repetitive seizures market in North America is mainly attributed to the presence of a large target population for epilepsy medications.
The acute repetitive seizures market in Europe is projected to register robust growth in terms of revenue over the forecast period, owing to the increased investment in neurology research & development and rising demand for epilepsy drugs. Besides, technological advancements in the scientific, therapeutic, and medical sectors would also boost growth. At the same time, government initiatives aimed at improving the quality of life and spreading awareness about the disease, as well as the promotion of better healthcare facilities, are the primary drivers of market growth in this region.
Asia Pacific Continues To Lead In Terms Of Revenue CAGR:
The Asia Pacific acute repetitive seizures market is expected to register rapid CAGR over the forecast period. Rising expenditure on healthcare is the major factor driving the APAC market growth. In this region, there is a significant gap in the management of acute repetitive seizures. As a result, the increased demand for anti-seizure medications in developing countries would further contribute to the APAC acute repetitive seizures market growth.
Major Companies Profiled In The Report:
Strategies And Objectives Of Major Companies:
What Our Report Provides And Why Our Offering Is Better:
This report offers historical data points and forecasts and revenue growth at a global, regional, and country level, and provides analysis, industry trends, and consumption pattern details for each region, major country, and segment from 2019 to 2030. The global market report includes industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and market share contribution by each regional and country market. In addition, the report offers industry analysis and competitive landscape, company financials, and impact analysis. The report includes a detailed view of the global market, along with changing dynamics and trends, scenarios, detailed market and regional segmentation, regional landscape, analysis and evaluation, major investments, product offerings, product launches, and details of historical, current, and projected revenues.
Detailed Segmentation In Our Report:
For the purpose of this report, global acute repetitive seizures market is segmented on the basis of product type, end-use, and region:
Product Type Outlook (Revenue, USD Billion; 2019-2030)
End-use Outlook (Revenue, USD Billion; 2019-2030)
Region Outlook (Revenue, USD Billion; 2019-2030)
Some points on how the report benefits stakeholders: